1. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis
   Dan Liu et al, 2017, BMC Cancer CrossRef
2. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver
   Rabih Said et al, 2015, Investigational New Drugs CrossRef
3. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients
   Pau Riera et al, 2021, Expert Opinion on Drug Metabolism & Toxicology CrossRef
4. A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients
   Jing Li et al, 2016, Journal of Cancer Research and Clinical Oncology CrossRef
5. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer
   Chunlei Xu et al, 2016, Cancer Chemotherapy and Pharmacology CrossRef
6. Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles
   K Venkatakrishnan et al, 2016, Clinical and Translational Science CrossRef
7. Management of chemotherapy dose intensity for metastatic colorectal cancer (Review)
   Xuelei Chu et al, 2022, Oncology Letters CrossRef
8. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation
   Erika Cecchin et al, 2018, Drug Resistance Updates CrossRef
9. Haplotype-Contained PCR Products Analysis by Sequencing with Selective Restriction of Primer Extension
   Liu Wang et al, 2017, BioMed Research International CrossRef
10. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab
    Guangrong Lu et al, 2022, Journal of Neuro-Oncology CrossRef
11. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial
    Sabine Tejpar et al, 2018, European Journal of Cancer CrossRef
12. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray
    Ryouichi Tsunedomi et al, 2017, Cancer Science CrossRef
13. Rapid and Sensitive Detection of UGT1A1 Polymorphisms Associated with Irinotecan Toxicity by a Novel DNA Microarray
    Ryouichi TSUNEDOMI, 2020, Yamaguchi Medical Journal CrossRef